Cariprazine

Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder. It is grouped under the following drug class(es): Mood stabilizers and Psychotropic agents. Its therapeutic use is listed as antipsychotics, central nervous system (CNS) agents and mood stabilizers. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Reagila and Cariprazine (RGH-188). Its PubChem CID is 11154555.